The U.S. Food and Drug Administration (FDA) created the role of Deputy Commissioner for Technology and Artificial Intelligence. Jared Seehafer will serve as the first appointee to this position. This role focuses on modernizing the regulatory framework for AI-driven innovation in drug discovery, clinical trials, and medical devices.
The agency also confirmed permanent leadership for two major divisions. Michael Davis, M.D., Ph.D., now leads the Center for Drug Evaluation and Research (CDER). Karim Mikhail will head the Center for Biologics Evaluation and Research (CBER). These appointments provide regulatory stability for the pharmaceutical and biotechnology sectors.
The new AI leadership signals an effort to accelerate the integration of artificial intelligence into regulated products. While this may streamline development and approval processes, it could also introduce new regulatory requirements. This shift directly impacts long-term research and development strategies for health tech and pharmaceutical companies.